Factors that affecting survival of patients with acute myeloid leukemia

authors:

avatar Alireza Akbarzadeh Baghban , avatar Hossein Hosseinifard ORCID , * , avatar Ahmad Reza Baghestani , avatar Saharnaz Ahmadi , avatar Mostafa Rezaei tavirani , avatar parviz Kokhaei

Koomesh: Vol.17, issue 3; 596-602
published online: September 28, 2016
article type: Research Article
received: October 01, 2015
accepted: February 01, 2016

how to cite: Akbarzadeh Baghban A, Hosseinifard H, Baghestani A R, Ahmadi S, Rezaei tavirani M, et al. Factors that affecting survival of patients with acute myeloid leukemia. koomesh. 2016;17(3):e151206. 

Abstract

Introduction: Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of blood producing cells and it’s one of the most common malignant disorders in adults. The aim of this study was to evaluate the blood parameters and the results of the liver function tests, as an effective prognosis for survival in AML patients hospitalized in Taleghani hospital, Tehran. Materials and Methods: In this cross-sectional study, patients (n=170) with AML diagnosis participated to study the laboratory results influencing their survival. Patients’ personal files were used as our source of data. Kaplan-Meier method and log-Rank tests were used for data analysis. Data modeling was performed using Cox regression model. Results: The mean and median survival time of patients were 14.13 ± 0.93 and 12.23 months respectively. Fitted model showed that factors such as age at the time of diagnosis, WBC count, smoking, family history, LDH and AST levels were associated with chance of survival in patients with AML. Conclusion: Our results showed that the age at the time of diagnosis, WBC count, smoking, family history, LDH and AST levels are effective factors on the chance of survival in AML patients. Therefore, considering these factors can increase the chance of survival in AML patients.

References

  • 1.

    Alsayyad J, Hamadeh R. Cancer incidence among the Bahraini population: a five-year (1998-2002) experience. Ann Saudi Med 2006; 27: 251-258.

  • 2.

    del Pilar Daz M, Osella AR, Aballay LR, Muoz SE, Lantieri MJ, Butinof M, et al. Cancer incidence pattern in Cordoba, Argentina. Eur J Cancer Prev 2009; 18: 259-266.

  • 3.

    Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009; 20: 556-563.

  • 4.

    Hutter JJ. Childhood leukemia. Pediatr Rev 2010; 31: 234-241.

  • 5.

    Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 43-50.

  • 6.

    Estey E, Dhner H. Acute myeloid leukaemia. Lancet 2006; 368: 907-1894.

  • 7.

    Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1083-1098.

  • 8.

    Mathews E, Laurie T, ORiordan K, Nabhan C. Liver involvement with acute myeloid leukemia. Case Rep Gastroenterol 2008; 2: 121-124.

  • 9.

    Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New Engl J Med 2005; 352: 254-266.

  • 10.

    Dinmohamed A, Visser O, van Norden Y, Blijlevens N, Cornelissen J, Huls G, et al. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 19892012. Leukemia 2016; 30: 24-31.

  • 11.

    Padilha SL, dos Santos Souza EJ, Matos MCC, Domino NR. Acute myeloid leukemia: survival analysis of patients at a university hospital of Paran. Rev Bras Hematol Hemoter 2015; 37: 21-27.

  • 12.

    Rauscher GH, Sandler DP, Poole C, Pankow J, Mitchell B, Bloomfield CD, et al. Family history of cancer and incidence of acute leukemia in adults. Am J Epidemiol 2002; 156: 517-526.

  • 13.

    Montesinos P, Daz-Mediavilla J, Debn G, Prates V, Tormo M, Rubio V, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 2009; 94: 1242-1249.

  • 14.

    Ribera JM, Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am 2009; 23: 1033-1042.

  • 15.

    Ayremlou P, Razavi SM, Solaymani-Dodaran M, Vakili M, Asadi-Lari M. Demographic and prognostic factors of 455 patients with acute leukemia admitted to Two referral hospitals in Tehran-Iran during Ten years (2001-2011). Iranian J Cancer Prev 2012; 5: 157.

  • 16.

    Ziaei JE. High frequency of acute promyelocytic leukemia in northwest Iran. Asian Pac J Cancer Prev 2004; 5: 188-189.

  • 17.

    Juliusson G, Antunovic P, Derolf , Lehmann S, Mllgrd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia registry. Blood 2009; 113: 4179-4187.

  • 18.

    Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia. Cancer 2013; 119: 2720-2727.

  • 19.

    Vardiman JW, Harris NL, Brunning RD. The world health organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.

  • 20.

    Chelghoum Y, Danaila C, Belhabri A, Charrin C, Le QH, Michallet M, et al. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol 2002; 13: 1621-1627.

  • 21.

    Aul C, Gattermann N, Germing U, Runde V, Heyll A, Schneider W. Risk assessment in primary myelodysplastic syndromes: validation of the Dusseldorf score. Leukemia 1994; 8: 1906-1913.

  • 22.

    Germing U, Hildebrandt B, Pfeilstcker M, Nsslinger T, Valent P, Fonatsch C, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223-2231.

  • 23.

    Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol 1996; 92: 627-631.

  • 24.

    Sperr W, Wimazal F, Kundi M, Fonatsch C, Thalhammer-Scherrer R, Schernthaner G, et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 2001; 80: 272-277.